Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

NCT ID: NCT03587844

Last Updated: 2025-11-03

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 58 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-07-03
• Study Completion Date: 2026-07-31

Brief Summary

The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.

Conditions

Mycosis Fungoides; Lymphomatoid Papulosis; Sezary Syndrome

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

not been previously treated with brentuximab vedotin.

Patients with MF/SS who have not been previously treated with brentuximab vedotin. For MF patients: Treatment delays lasting longer than 8 weeks for toxicity will result in removal from study. As of October 2020, the Simon two stage design for Cohort 1 has restarted at the 1.2 mg/kg dose.

Group Type: EXPERIMENTAL

brentuximab vedotin

Intervention Type: DRUG

MF/SS Brentuximab vedotin 0.9 mg/kg 0R 1.2 mg/kg.

treated with reduced dose brentuximab vedotin

Patients with MF/SS who were previously treated with brentuximab vedotin. Up to 10 patients will be enrolled onto this cohort. Following identification of a promising dose after the completion of the full Cohort 1 Simon two stage design, enrollment will initiate onto cohort 2 at the dose found to be promising in cohort 1. For MF patients: Treatment delays lasting longer than 8 weeks for toxicity will result in removal from study. The 0.9mg/kg dose did not meet the primary endpoint for response, therefore 1.2 mg/kg has been chosen as the dose for Cohort 2. As of October 2020, enrollment on our exploratory Cohort 2 has opened at the 1.2 mg/kg dose.

Group Type: EXPERIMENTAL

brentuximab vedotin

Intervention Type: DRUG

MF/SS prior brentuximab vedotin-Brentuximab vedotin dose to be determined from Cohort 1

Patients with LyP

Patients with LyP patients with lymphomatoid papulosis will receive brentuximab vedotin 0.9 mg/kg as an intravenous infusion over 30 minutes every three weeks. Cohort 3 will enroll patients concurrently with Cohort 1. Treatment may be held if felt to be in patient's best interest (for example: for toxicity or no active disease). Treatment can be reinitiated after discussion with MSK PI as long as the study is still open and patient has not received alternate systemic therapy.

Group Type: EXPERIMENTAL

brentuximab vedotin

Intervention Type: DRUG

LyP Brentuximab vedotin 0.9 mg/kg2

Interventions

brentuximab vedotin

MF/SS Brentuximab vedotin 0.9 mg/kg 0R 1.2 mg/kg.

Intervention Type: DRUG

brentuximab vedotin

LyP Brentuximab vedotin 0.9 mg/kg2

Intervention Type: DRUG

brentuximab vedotin

MF/SS prior brentuximab vedotin-Brentuximab vedotin dose to be determined from Cohort 1

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Mycosis fungoides (MF) and Sezary Syndrome (SS)

1. Pathologically confirmed mycosis fungoides/sezary syndrome at the enrolling institution, disease stage IB (defined as patches, plaque, or papules that involve 10% of the skin surface viscera) or higher

° CD30 negative mycosis fungoides patients are eligible.

2. Age ≥ 18 years

3. ECOG Performance Score ≤ 2

4. For Cohort 1, patients who have not received brentuximab vedotin are eligible.

5. For Cohort 2, patients who have previously had brentuximab vedotin for MF/SS are eligible. Patients previously treated on Cohort 1 who were discontinued due to toxicity are not eligible for Cohort 2.

6. Previous systemic anti-cancer therapy must have been discontinued at least 2 weeks prior to treatment.

Exclusion Criteria

7. Topical or systemic steroids (equivalent to ≤ 10 mg/day of prednisone) may be considered if dose has been constant and discontinuation may lead to rebound flare in disease, adrenal insufficiency, and/or unnecessary suffering, after discussion with PI.

8. If HIV+, patient must be on stable anti-retroviral treatment for 12 weeks prior to C1D1, with CD4 count >200 within 7 days prior to C1D1.

9. Females of childbearing potential must be on acceptable form of birth control per instutional standard.

Lymphomatoid papulosis (LyP)

1. Pathologically confirmed lymphomatoid papulosis at the enrolling institution

2. Requiring systemic treatment per investigator's discretion

3. Age ≥ 18 years

4. ECOG Performance Score ≤ 2

5. Previous systemic anti-cancer therapy must have been discontinued at least 2 weeks prior to treatment.

6. Topical or systemic steroids (equivalent to ≤ 10 mg/day of prednisone) may be considered if dose has been constant and discontinuation may lead to rebound flare in disease, adrenal insufficiency, and/or unnecessary suffering.

7. If HIV+, patient must be on stable anti-retroviral treatment for 12 weeks prior to C1D1, with CD4 count >200 within 7 days prior to C1D1.

8. Females of childbearing potential must be on acceptable form of birth control per institutional standard

1. Concurrent use of other systemic anti-cancer agents or treatments for mycosis fungoides/sezary syndrome, or lymphomatoid papulosis.

2. Grade 2 or greater neuropathy

3. Severe renal impairment (CrCL <30 mL/min)

4. Moderate or severe hepatic impairment (Child-Pugh B or Child-Pugh C)

° See Appendix E for Child Pugh Classification chart

5. Women of reproductive potential† must have a negative Serum ß human chorionic gonadotropin (ß-HCG) pregnancy test within 1 week of C1D1. They should discuss contraception with treating provider.

6. Previous use of brentuximab vedotin (for Cohort 1 ONLY)

7. Receiving systemic therapy for another primary malignancy (other than T-cell lymphoma).

• Patients with more than one type of lymphoma may be enrolled after discussion with the MSK Principal Investigator.
• Adjuvant or maintenance therapy to reduce the risk of recurrence of other malignancy (other than T-cell lymphoma) is permissible after discussion with the MSK Principal Investigator.

8. For Cohort 2, patients who previously progressed on the standard 1.8mg/kg dose and schedule of brentuximab vedotin are ineligible.

• A female of reproductive potential is a sexually mature female who: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive months (i.e. has had menses at any time in the preceding 24 consecutive months).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Seagen Inc.

INDUSTRY

Sponsor Role: collaborator

Memorial Sloan Kettering Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alison Moskowitz, MD

Role: PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Locations

Stanford University Medical Center

Stanford, California, United States

Site Status: RECRUITING

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, United States

Site Status: RECRUITING

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, United States

Site Status: RECRUITING

Memorial Sloan Kettering Bergen

Montvale, New Jersey, United States

Site Status: RECRUITING

Memorial Sloan Kettering Commack

Commack, New York, United States

Site Status: RECRUITING

Memorial Sloan Kettering Westchester

Harrison, New York, United States

Site Status: RECRUITING

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Site Status: RECRUITING

Memorial Sloan Kettering Nassau

Uniondale, New York, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Alison Moskowitz, MD

Role: CONTACT

moskowia@mskcc.org

646-608-3726

Patricia Myskowski, MD

Role: CONTACT

646-608-2351

Facility Contacts

Youn Kim, MD

Role: primary

650-498-6000

Alison Moskowitz, MD

Role: primary

646-608-3726

Alison Moskowitz, MD

Role: primary

646-608-3726

Alison Moskowitz, MD

Role: primary

646-608-3726

Alison Moskowitz, MD

Role: primary

646-608-3726

Alison Moskowitz, MD

Role: primary

646-608-3726

Alison Moskowitz, MD

Role: primary

646-608-3726

Patricia Myskowski, MD

Role: backup

646-608-2351

Alison Moskowitz, MD

Role: primary

646-608-3726

Related Links

http://www.mskcc.org/mskcc/html/44.cfm

Memorial Sloan Kettering Cancer Center

Other Identifiers

18-147

Identifier Type: -

Identifier Source: org_study_id